Press Release|Articles|December 2, 2024

Camber Pharmaceuticals Introduces Lidocaine HCI Injection, USP, in Single- and Multi-Dose Vials

Listen

0:00 / 0:00

Key Takeaways

Camber Pharmaceuticals introduces Lidocaine HCl Injection in single-dose and multi-dose vials with 1% and 2% concentrations.
The product is available in various vial and pack sizes to meet diverse healthcare needs.
Camber, a subsidiary of Hetero, focuses on delivering high-quality generic medications for cost-effective healthcare solutions.
Expertise in APIs and finished dosage manufacturing ensures global access to affordable, reliable pharmaceuticals.

Featuring 1% and 2% concentrations, this versatile product is available in various vial and pack sizes to meet diverse healthcare needs.

Camber Pharmaceuticals is excited to introduce Lidocaine HCl Injection, USP, in Single-Dose and Multi-Dose Vials. Featuring 1% and 2% concentrations, this versatile product is available in various vial and pack sizes to meet diverse healthcare needs.

Click below to learn more:

Single-Dose Vials: https://www.camberpharma.com/products/lidocaine-sdv/
Multi-Dose Vials: https://www.camberpharma.com/products/lidocaine-mdv/

Camber Pharmaceuticals, a fully integrated pharmaceutical company, is dedicated to delivering high-quality generic medications that enhance lives through cost-effective healthcare solutions. As a subsidiary of Hetero, a global leader in active pharmaceutical ingredients (APIs) and finished dosage manufacturing based in Hyderabad, India, Camber leverages its expertise to ensure access to affordable, reliable pharmaceuticals for consumers worldwide.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

Webinar Registration

Redefining Metabolic Dysfunction-Associated Steatohepatitis Treatment: Managed Care Insights on New Therapies Targeting Metabolic Dysfunction

Tuesday, June 16, 2026 | 1:00 PM and 7:00 PM EDT

Virtual Symposium Registration

Not All Bispecifics Are Equal: Mechanism-Based Approaches to Selection and Management in Oncology Practice

Thursday, June 18, 2026 | 7:00 AM - 8:00 AM CT

In-Person Conference

Oncology Pharmacists Connect 2026

June 18-19, 2026

Panel Discussion Registration

The Educated Pharmacist: Using Patient Insights to Personalize Insulin Therapy and Prevent Clinical Inertia

Thursday, June 25, 2026 | 1:00 PM – 2:30 PM EDT

Camber Pharmaceuticals Introduces Lidocaine HCI Injection, USP, in Single- and Multi-Dose Vials

Key Takeaways

Related Content

Camber Launches Abacavir and Lamivudine Tablets, USP

Camber Launches Colchicine Capsules

Camber Pharmaceuticals Adds Metformin Hydrochloride Oral Solution to Growing Portfolio

Camber Launches Prucalopride Tablets

Camber Announces Addition of Chlorpromazine HCl Injection, USP

Latest CME

Redefining Metabolic Dysfunction-Associated Steatohepatitis Treatment: Managed Care Insights on New Therapies Targeting Metabolic Dysfunction

Not All Bispecifics Are Equal: Mechanism-Based Approaches to Selection and Management in Oncology Practice

Oncology Pharmacists Connect 2026

The Educated Pharmacist: Using Patient Insights to Personalize Insulin Therapy and Prevent Clinical Inertia

Managing Iron Replacement Therapies for Patients With Inflammatory Bowel Disease

Breast Cancer Day of Education 2026

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Immunology Specialty Pharmacy Day of Education 2026

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Targeting Genomic Drivers to Optimize ROS1-Directed Therapy in NSCLC

From Molecule to Medication: Integrating Menin Inhibitors in AML Practice

Enhancing Patient Outcomes in Metastatic Colorectal Cancer: Equipping Community, Veterans Affairs, and Oncology Pharmacists to Navigate Care in the Third-Line Setting and Beyond

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Optimizing Therapy in HR+/HER2-Negative Metastatic Breast Cancer: Navigating Novel Treatments and Personalized Care

Expert Insights on the Horizon of HER2-Directed Therapy

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

The Pharmacist's Role in Palliative and End of Life Symptom Management

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Addressing Vaccine Hesitancy in Infectious Disease Prevention

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Beyond the Prescription: Tackling Social Isolation for Better Health (Pharmacy Technician Credit)

Understanding and Personalizing Chronic Obstructive Pulmonary Disease Diagnosis and Treatment

Evaluating the Role of Pharmacists in Utilizing Potassium-Competitive Acid Blockers for Acid Peptic Disorders

Balancing Pain Management and Opioid Use Disorder: Recognition, Treatment, and Compassionate Communication in Pharmacy Practice